Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lidocaine + naproxen
- Development stage
- Preclinical
- Lead developer
- Scilex Holding
- Modality
- Small Molecules
- Administration
- Intrauterine, Oral, Topical
01
Overview
A pharmaceutical combination of lidocaine, a local anesthetic that blocks sodium channels to prevent nerve impulse transmission, and naproxen, a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation and pain. This combination provides complementary pain relief through different mechanisms of action.
- Other names
- naproxen and lidocainenaproxen/lidocaine
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NaV (Voltage-gated sodium channels)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on lidocaine + naproxen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lidocaine + naproxen.